The American Society of Breast Surgeons (ASBrS) encourages an evidence-based and patient value focused approach to contralateral prophylactic mastectomy (CPM). The ASBrS convened a panel of experts to develop a consensus statement on CPM. The majority of women will obtain no oncologic benefit from CPM, and therefore CPM should be discouraged in average-risk women with unilateral breast cancer. Consideration of the patient’s preferences and values and an informed discussion of the risks and benefits of CPM is recommended for all patients pursuing mastectomy, along with a direct recommendation by the surgeon for or against CPM.

**SENTINEL LYMPH NODE SURGERY FOR CPM**

The benefit of performing sentinel lymph node (SLN) surgery at the time of CPM is that the lymph nodes have been evaluated in the event that an occult malignancy is found, but the downside is increased surgical morbidity such as lymphedema. By meta-analysis, the risk of lymphedema after SLN alone is 5.6 % (95 % CI 6.1–7.9 %) and increases with longer follow-up. The chance of finding occult invasive disease in a prophylactic mastectomy is 1.8 %. An additional small percent of CPM specimens harbor noninvasive disease that would not require nodal evaluation. The rate of nodal positivity in patients with occult malignancy in CPM is only 1.3 %. Considering these data, routine SLN surgery at time of CPM places more patients at risk of lymphedema than would be expected from the 1–2 % of patients with occult disease undergoing axillary dissection. Therefore the consensus group does not recommend routine SLN for CPM.

Patients at higher risk of contralateral occult malignancy are postmenopausal patients, those with triple-negative, locally advanced, inflammatory, or invasive lobular disease. MRI at the time of breast cancer diagnosis identifies occult contralateral disease 2–4 % of the time. Suspicious lesions in the contralateral breast should be biopsied, but if a biopsy is not done, SLN surgery should be considered for highly suspicious lesions.

**Summary** Sentinel lymph node surgery on the CPM side should not be routinely performed.
COST OF CPM VERSUS SURVEILLANCE

There is robust literature to support the use of CPM as a cost-effective strategy in patients with hereditary breast cancer syndromes. Anderson et al. demonstrated that the most cost-effective strategy, with and without quality adjustment, for women with BRCA1 or BRCA2 mutations was prophylactic bilateral salpingo-oophorectomy with bilateral mastectomy. Simulation models analyzing costs for CPM versus surveillance in patients with sporadic breast cancer reveal disparate findings. An initial Markov model study found that CPM was cost-effective compared with surveillance for patients younger than 70 years, but this finding was highly dependent on the quality of life assumptions. A second study that included operative complications and breast reconstruction costs used a decision-tree model and concluded that although CPM resulted in a cost savings over surveillance for women younger than 50 years, it also reduced quality of life years. When MRI was inserted in the model as the primary method of screening, the cost-effectiveness of CPM increased. Loss of quality of life years was largely attributed to complications from reconstructive procedures. The two models differ in the assumptions regarding quality of life. If we assume an improvement in quality of life after CPM, then CPM could be cost-effective. Alternatively, if quality of life is decreased, CPM would not be a cost-effective strategy. The available data on cost effectiveness for CPM is limited to modeling studies and therefore does not provide strong scientific evidence to support CPM as a cost-effective strategy.

Summary CPM is a cost-effective strategy for women with BRCA mutations. At this time, there is insufficient evidence to support the concept of superior cost-effectiveness for CPM in women with sporadic breast cancer and the cost effectiveness is highly dependent on the quality of life assumptions.

IMPACT OF CPM ON PSYCHOSOCIAL OUTCOMES

The decision to undergo CPM is intensely personal and frequently driven by a shifting balance between perceived future breast cancer risk, anxiety over annual screening and potential future diagnostic procedures, and the unknown physical, emotional, and cosmetic outcomes of the surgery. Long-term outcomes for women who have undergone CPM report that 86–90% of respondents were satisfied with the decision to undergo prophylactic surgery. With 20 years of follow-up more than 90% of women definitely or probably would choose to undergo CPM again. However, many of these same women report dissatisfaction with areas such as body image, chronic pain, problems with implants, and sexual changes even though they noted overall satisfaction with their decision-making. In a study of 296 women who participated in the National Prophylactic Mastectomy Registry and provided detailed responses to a survey evaluating their outcomes with CPM, only 6% expressed regrets with the decision; but of these women 39% reported poor cosmetic outcomes and 22% reported a reduced sense of sexuality. Studies with longer follow-up had outcome data only on a proportion of the initial cohort, introducing possible bias between responders and nonresponders, limiting the strength of the evidence.

Few studies have examined quality of life between CPM and non-CPM patients. One study, approximately 10 years ago, showed no difference in quality of life between patients undergoing CPM and those undergoing unilateral mastectomy or lumpectomy. In a study from Sweden, no differences in overall health-related quality of life were identified up to two years post surgery in 60 women undergoing (delayed) CPM.

Summary While 80–90% of women report satisfaction with their decision to undergo CPM, 20–30% of these women report postsurgical dissatisfaction with cosmesis, body image, and sexuality. Studies show that CPM does not affect overall quality of life parameters. Women should be counseled on the potential long-term outcomes of CPM on body image and sexuality.

SHOULD PERFORMANCE OF CPM BE A QUALITY MEASURE?

Quality measures are used to compare the performance of individual surgeons or institutions and can be viewed as “external” or “internal”. External quality measures can support pay-for-performance programs or be used for public reporting and are designed to help patients and purchasers make healthcare choices among providers, while internal measures are primarily used to identify quality-improvement initiatives within a given healthcare system or hospital. In evaluating the use of CPM as a quality measure, the most important consideration is how it would impact behavior of the surgeon, hospitals, purchasers, and payors and ultimately patient care. If CPM is a publicly reported measure, one could argue that patients could self-select for surgeons who align with their preferences based on reported CPM rates, but it could also pressure surgeons to decline to perform this procedure. CPM should not be used as a high-stakes quality measure such as for public reporting or selective referral because of a lack of a clearly defined outcome that is improved for all
patients, ambiguity around exclusion criteria for the denominator, and significant potential for unintended consequences that can limit access to appropriate care.

The best potential for CPM is as an internal measure to inform performance review and quality-improvement efforts. Quality measures that are used for internal reporting do not require the same level of rigor and validity as those used for higher-stakes measurement. Such quality measures can be critical in determining the etiology of overutilization, particularly for a procedure such as CPM where there is wide variation in observed rates by surgeon and hospital that may represent provider bias rather than patient preference.

In summary, the use of CPM as a quality measure is limited because of a lack of a clear association with an improved outcome and its potential for unintentionally decreasing access to patients who may be at high risk for contralateral cancer. Internal measurement to inform a better understanding of the role physician and institutional bias and practice patterns could play in driving the observed increased utilization of CPM is the only potential application at this time. The ultimate goal of CPM as an internal quality measure is to minimize unnecessary, risky surgery and to track the effectiveness of new shared decision models as they become available.

Summary CPM should not be used as a national quality measure.

PERSPECTIVES ABOUT CONTRALateral PROPHYLACTIC MASTECTOMY FROM OTHER COUNTRIES: THE UNITED KINGDOM AND MAINLAND EUROPE

The United Kingdom has significantly lower rates of CPM than the United States, although recently rates of CPM have increased in the United Kingdom with one study showing an increase from 2.0 to 3.1%. In Switzerland, studies have not shown any increased trend for CPM. Senior surgeons on the European Breast Cancer Board (UEMS) do not feel CPM is increasing in Scandinavia, Spain, Austria, or central Europe (personal communication). CPM drivers in the United Kingdom are similar to the United States, including influence of the media, poor understanding of the risks of relapse and the limited impact of CPM on these risks, poor understanding of contralateral breast cancer risk and risks associated with breast reconstruction, and fear of recurrence. In addition, increased access to breast reconstruction, desire for symmetry, and worry about missing future cancers from mammogram screening also motivate patients to pursue CPM. A multidisciplinary approach to managing requests for CPM has been shown to reduce CPM rates.

One key difference between the United Kingdom and the United States is that most private health insurers and some National Health Service commissioners in the United Kingdom will not fund CPM unless the patient is a BRCA carrier. Another key difference between the two countries is that breast surgeons in the United Kingdom learn to perform oncoplastic procedures as part of their formal training and therefore more commonly perform oncoplastic breast conservation to maintain symmetry.

UK/European Guidelines

- UK Breast Cancer clinical reference group (2016) states “There is no evidence of a survival benefit for contralateral risk-reducing mastectomy—this should not be offered, except for women with BRCA mutations, and should only be performed after a full discussion of the risks and benefits and with appropriate psychological support.”
- The National Institution for Health and Care Excellence (NICE) has no recommendations about CPM, but guidelines are due for review 2016/2017.
- EUSOMA (the European Society of Breast Cancer Specialists) and EUROPA DONNA (the European Breast Cancer Coalition) do not have any published guidelines.

Summary CPM rates are rising in the United Kingdom but not mainland Europe. CPM drivers are similar between the United Kingdom and the United States. Payment for CPM is not as freely available in Europe as in the United States.

PATIENT PERSPECTIVES ON CPM

In numerous studies, many patients arrived at a decision to have a CPM based on two main themes—a decision based in fear or a decision to “take control.” Patient’s fear translated into an “overestimated risk of recurrence, contralateral breast cancer, and death.” Breast cancer surgical treatment decisions are made when a patient’s best decision-making skills are severely impaired by the stress and anxiety of their cancer diagnosis.

The increased media focus on surgical treatment options exploded after Angelina Jolie, a prominent celebrity and actress, announced her decision to undergo bilateral prophylactic mastectomy after finding out she was a BRCA1 gene mutation carrier. This increased media exposure for a woman choosing bilateral mastectomy raised the visibility of prophylactic surgical options and generated considerable confusion for other newly diagnosed patients as to whether a CPM was indicated for them. This confusion has surfaced in decision-making conversations with patients and surgeons when discussing surgical options.

Ultimately, fear of cancer recurrence and input from family and friends influence decisions to undergo
SHARED DECISION MAKING FOR CPM

Most women who have undergone CPM report having taken an active role in the decision process, with roughly 45–57 % reporting making the decision mainly on their own, and only 15–38 % reporting sharing in the decision process.\(^{20,37}\) Although the majority of patients who contemplate CPM identify their physicians as a key source of information, in a cohort of young women (younger than 40 years), few rate a desire to follow physician recommendations as very important in their decision making.\(^{38}\) Critical factors that were highly important to patients in the CPM decision-making process included: reducing their chance of a CBC (98 %), achieving peace of mind (95 %), improving survival/extending life (94 %), feeling at increased risk for CBC (87 %), and preventing metastatic spread (85 %).\(^{38}\)

Many patients consider CPM prior to seeing their surgeon. In a recent study, more than 50 % of women with sporadic breast cancer were initially interested in CPM, but only 10 % underwent CPM.\(^{39}\) Although patients claim CPM discussion rates of 45–80 % with their doctor, only half of patients relay that their doctors outlined reasons not to have CPM.\(^{38,39}\) Given that approximately one-third of patients in one study experienced worse than expected results, this discussion may serve as an educational opportunity for providers to optimize informed consent.\(^{20}\) An accurate model that provides realistic numbers regarding CBC risk and impact of CPM and incorporates patient desires and other psychosocial factors may serve to enhance shared decision making between the patient and provider.

Summary Shared decision making that includes a comprehensive discussion of risks and benefits of CPM is important.

COUNSELING PATIENTS ON CONTRALATERAL PROPHYLACTIC MASTECTOMY

Surgeons should strive to help patients make decisions that are informed and evidence based. They should encourage patients to make decisions that are concordant with their personal values. They should inform patients about the low risk of CBC for most patients, how CPM impacts survival and recurrence, complications and risks of CPM, and how CPM can impact body image and cosmesis. Asking patients about the importance of keeping the breast, perspectives on radiation, the importance of breast symmetry to body image, and the importance of removing the breast for peace of mind all help differentiate between those patients wanting mastectomy versus breast conservation.\(^{40}\) Surgeons should encourage patients to actively participate in the decision-making process and try to elicit patient’s treatment preferences. Since many patients consider CPM somewhere in their decision-making process, surgeons should make a recommendation based on their expert opinion after weighing the evidence and reviewing the risks and benefits of CPM with the patient.\(^{39}\) The surgeon is responsible for informing the patient about CPM’s impact on outcomes, both physical and psychological, engaging the patient in the decision-making process, and ensuring that patients are making treatment decisions that are concordant with their personal values and goals.
The consensus group has compiled a template of information that providers should include in the discussion with every patient considering CPM for unilateral breast cancer (excluding high-risk patients such as BRCA carriers) (Table 1). It is highly recommended that surgeons incorporate this template into conversations with patients to ensure that patients are making high-quality decisions about their breast surgery.

Summary CPM counseling should include discussion of CPM, risks of CPM, rates of CBC, and ensure patients are engaged in the decision making, and making decisions that are concordant with their treatment preferences and personal values.

**OPEN ACCESS** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**REFERENCES**

1. Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy consensus statement from the American Society of Breast Surgeons: the data on CPM outcomes and risks. *Ann Surg Oncol.* 2016.
2. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. *Lancet Oncol.* 2013;14:500–15.
3. Boughey JC, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. *Cancer.* 2006;107:1440–7.
4. Nagaraja V, Ediriranne S, Eslick GD. Is sentinel lymph node biopsy necessary in patients undergoing prophylactic mastectomy? A systematic review and meta-analysis. *Breast J.* 2016;22:158–65.
5. Yi M, Meric-Bernstam F, Middleton LP, et al. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. *Cancer.* 2009;115:962–71.
6. Murthy V, Chamberlain RS. Prophylactic mastectomy in patients at high risk: is there a role for sentinel lymph node biopsy? *Clin Breast Cancer.* 2013;13:180–7.
7. Boughey JC, Cormier JN, Xing Y, et al. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. *Cancer.* 2007;110:2542–50.
8. Nasser SM, Smith SG, Chagpar AB. The role of sentinel node biopsy in women undergoing prophylactic mastectomy. *J Surg Res.* 2010;164:188–92.
9. Laronga C, Lee MC, McGuire KP, Meade T, Carter WB, Hoover S, Cox CE. Indications for sentinel lymph node biopsy in the setting of prophylactic mastectomy. *J Am Coll Surg.* 2009;209:746–52.
10. Czyszczon IA, Roland L, Sahoo S. Routine prophylactic sentinel lymph node biopsy is not indicated in women undergoing prophylactic mastectomy. *J Surg Oncol.* 2012;105:650–4.
11. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. *N Engl J Med.* 2007;356:1295–303.
12. Anderson K, Jacobson JS, Heitijan DF, Zivin JG, Hershman D, Neugut AI, Grann VR. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. *Ann Intern Med.* 2006;144:397–406.
13. Grann VR, Patel PR, Jacobson JS, et al. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. *Breast Cancer Res Treat.* 2011;125:837–47.
14. Cott Chubiz JE, Lee JM, Gilmore ME, et al. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. *Cancer.* 2013;119:1266–76.
15. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. *N Engl J Med.* 2004;351:427–37.
16. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. *J Natl Cancer Inst.* 2009;101:80–7.
17. Zendjes B, Moriarti JP, O’Byrne J, Degnim AC, Farley DR, Boughey JC. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. *J Clin Oncol.* 2011;29:2993–3000.
18. Roberts A, Habibi M, Frick KD. Cost-effectiveness of contralateral prophylactic mastectomy for prevention of contralateral breast cancer. *Ann Surg Oncol.* 2014;21:2209–17.
19. Frost MH, Slezkj JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. *J Clin Oncol.* 2005;23:7849–56.
20. Rosenberg SM, Sepucha K, Ruddy KJ, et al. Local therapy decision-making and contralateral prophylactic mastectomy in young women with early-stage breast cancer. *Ann Surg Oncol.* 2015;22:3809–15.
21. Geiger AM, West CN, Neklyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. *J Clin Oncol.* 2006;24:1350–6.
22. Frost MH, Hoskin TL, Hartmann LC, Degnim AC, Johnson JL, Boughey JC. Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. *Ann Surg Oncol.* 2011;18:3110–6.
23. Altschuler A, Neklyudov L, Rolnick SJ, et al. Positive, negative, and disparate—women’s differing long-term psychosocial experiences of bilateral or contralateral prophylactic mastectomy. *Breast J.* 2008;14:25–32.
24. Montgomery LL, Tran KN, Heelan MC, Van Zee KJ, Massie MJ, Payne DK, Borgen PI. Issues of regret in women with contralateral prophylactic mastectomies. *Ann Surg Oncol.* 1999;6:546–52.
25. Unukovych D, Sandelin K, Liljegren A, Arver B, Wickman M, Johansson H, Brandberg Y. Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2-years follow-up study of health related quality of life, sexuality and body image. *Eur J Cancer.* 2012;48:3150–6.
26. Neuberger J, MacNeill F, Jeevan R, van der Meulen JH, Cromwell DA. Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics. *BMJ Open.* 2013;3:e003179.
27. Guth U, Myrick ME, Viehl CT, Weber WP, Lardi AM, Schmid SM. Increasing rates of contralateral prophylactic mastectomy—a trend made in USA? *Eur J Surg Oncol.* 2012;38:296–301.
28. Basu NN, Littlechild S, Evans DG, Ross G, Barr L. Contralateral risk reducing mastectomy—a national survey of surgeons’ practices and perceptions. *Eur J Surg Oncol.* 2013;39:S64.
29. Leff DR, Ho C, Thomas H, et al. A multi-disciplinary team approach minimises prophylactic mastectomy rates. Eur J Surg Oncol. 2015;41:1005–12.

30. Covelli AM, Baxter NN, Fitch MI, McCready DR, Wright FC. ‘Taking control of cancer’: understanding women’s choice for mastectomy. Ann Surg Oncol. 2015;22:383–91.

31. Rosenberg SM, Partridge AH. Contralateral prophylactic mastectomy: an opportunity for shared decision making. JAMA Surg. 2014;149:589–90.

32. Borzekowski DL, Guan Y, Smith KC, Erby LH, Roter DL. The Angelina effect: immediate reach, grasp, and impact of going public. Genet Med. 2014;16:516–21.

33. Soran A, Ibrahim A, Kanbour M, et al. Decision making and factors influencing long-term satisfaction with prophylactic mastectomy in women with breast cancer. Ann J Clin Oncol. 2015;38:179–83.

34. Hawley ST, Jagsi R, Morrow M, Janz NK, Hamilton A, Graff JJ, Katz SJ. Social and clinical determinants of contralateral prophylactic mastectomy. JAMA Surg. 2014;149:582–9.

35. Pantalon MV Sledge WH, Bauer SF, et al. Important medical decisions: Using brief motivational interviewing to enhance patients’ autonomous decision-making. J Psychiatr Pract. 2013;19:98–108.

36. Akechi T, Momino K, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Iwata H. Contribution of problem-solving skills to fear of recurrence in breast cancer survivors. Breast Cancer Res Treat. 2014;145:205–10.

37. Nekhlyudov L, Bower M, Herrinton LJ, et al. Women’s decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst. 2005;97:55–60.

38. Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 2013;159:373–81.

39. Parker PA, Peterson SK, Bedrosian I, et al. Prospective study of surgical decision-making processes for contralateral prophylactic mastectomy in women with breast cancer. Ann Surg. 2016;263:178–83.

40. Sepucha KR, Fowler FJ, Jr., Mulley AG, Jr. Policy support for patient-centered care: the need for measurable improvements in decision quality. Health Aff (Millwood). 2004;Suppl Variation:VAR54–62.